ArticleACS omega2025
The Allosteric Inhibitor Pentachloropseudilin Inhibits Myosin 1C ATPase Activity and Recapitulates Retinitis Pigmentosa Phenotypes in Mice.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unconventional myosins are molecular motors that move along actin filaments in an ATPase-dependent manner, thereby influencing intracellular cargo transport. Dysfunction of myosins due to loss-of-function mutations causes human disease phenotypes such as deafness, retinitis pigmentosa, renal failure, and hypertrophic cardiomyopathy. However, some genetic models lacking unconventional myosins do not recapitulate the retinal phenotypes observed in humans, necessitating alternative approaches. We previously showed that the myosin motor protein MYO1C is required for the trafficking of rhodopsin in mouse photoreceptors and for visual function. To investigate whether MYO1C could be nongenetically inhibited, we used the natural compound pentachloropseudilin (PCIP) to allosterically inhibit MYO1C-ATPase motor activity. PCIP treatment of COS1 cells coexpressing GFP-rhodopsin and mCherry-MYO1C resulted in an aggregation of GFP-rhodopsin protein in the cytoplasm and impaired the kinetics of rhodopsin foci movement. Conversely, GFP-rhodopsin trafficked efficiently to the plasma membrane in non-PCIP-treated COS1 cells. PCIP effects in vivo were then analyzed in wild-type mouse retinas based on evaluations of opsin trafficking, visual response measurements using ERGs, and quantification of rhodopsin recovery rates after photobleaching. Intravitreous injections of PCIP into WT mice caused significant rhodopsin mislocalization and shorter rod photoreceptor outer segments, resulting in reduced scotopic visual responses, thereby recapitulating retinitis pigmentosa phenotypes commonly observed in humans. Our study provides evidence from live-cell analysis and vertebrate retinas that using PCIP can recapitulate the retinal phenotypes observed in humans with myosin mutations. Furthermore, it confirms in a nongenetic model the requirement for MYO1C in photoreceptor opsin trafficking, maintenance of photoreceptor outer segments, and visual function.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.